FOXM1 Promotes Non-Small Cell Lung Cancer Progression by Increasing CHEK1 Expression

Abstract

Objective

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-associated mortality. This study aimed to investigate the role of checkpoint kinase 1 (CHEK1) in NSCLC progression and its regulatory relationship with forkhead box protein M1 (FOXM1).

Methods

Transwell assays were used to evaluate the migration and invasion capabilities of NSCLC cells with either CHEK1 overexpression or knockdown. The expression of epithelial−mesenchymal transition (EMT) markers in NSCLC cells under CHEK1 overexpression or knockdown conditions was analyzed via Western blotting. Proliferative capacity was assessed using CCK-8 assays in NSCLC cells with modulated CHEK1 expression. Additionally, real-time quantitative PCR was employed to measure CHEK1 and FOXM1 expression levels in NSCLC tissues. The effects of CHEK1 knockdown on tumor growth were further validated in animal models. The binding of FOXM1 to the CHEK1 promoter region was examined using dual-luciferase reporter assays and chromatin immunoprecipitation (ChIP) assays.

Results

FOXM1 and CHEK1 were upregulated in NSCLC tissues. CHEK1 overexpression promoted NSCLC cell proliferation, while its knockdown suppressed proliferation, inhibited EMT, and reduced tumor growth in vivo. FOXM1 was shown to directly bind to CHEK1 promoter, thereby upregulating CHEK1 expression.

Conclusion

CHEK1 promotes NSCLC cell proliferation and tumor growth, and its expression is regulated by FOXM1. These findings suggest CHEK1 and FOXM1 are potential therapeutic targets for NSCLC treatment.

Keywords

Non-small cell lung cancer / Checkpoint kinase 1 / Forkhead box protein M1 / Transcriptional activation / Therapeutic targets

References

[1] AlessiJV, ElkriefA, RicciutiB, et al.. Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC. J Thorac Oncol., 2023, 18(6): 731-743.

[2] AlduaisY, ZhangH, FanF, et al.. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore), 2023, 1028. e32899

[3] LahiriA, MajiA, PotdarPD, et al.. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer., 2023, 22140.

[4] WuJ, LinZ. Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance. Int J Mol Sci, 2022, 232315056.

[5] SalgiaR, PharaonR, MambetsarievI, et al.. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med, 2021, 21. 100186

[6] RundleS, BradburyA, DrewY, et al.. Targeting the ATR-CHK1 axis in cancer therapy. Cancers (Basel), 2017, 9541.

[7] LiuXP, HuangQ, YinXH, et al.. Strong correlation between the expression of CHEK1 and clinicopathological features of patients with multiple myeloma. Crit Rev Eukaryot Gene Expr, 2020, 30(4): 349-357.

[8] BaoS, WuQ, McLendonRE, et al.. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120): 756-760.

[9] QiuZ, OleinickNL, ZhangJ. ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol., 2018, 126(3): 450-464.

[10] AlorjaniM, AburubM, Al-TradB, et al.. The prevalence of CHEK1 and CHEK2 mutations in prostate cancer: a retrospective cohort study. Med Arch, 2023, 77(1): 8-12.

[11] LevyA, Albiges-SauvinL, MassardC, et al.. Cell cycle, mitosis and therapeutic applications. Bull Cancer, 2011, 98(9): 1037-1045.

[12] CarrassaL, DamiaG. Unleashing Chk1 in cancer therapy. Cell Cycle, 2011, 10(13): 2121-2128.

[13] SaeedN, MahjabeenI, HakimF, et al.. Role of Chk1 gene in molecular classification and prognosis of gastric cancer using immunohistochemistry and LORD-Q assay. Future Oncol, 2022, 18(25): 2827-2841.

[14] KristeleitR, PlummerR, JonesR, et al.. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. Br J Cancer, 2023, 129(1): 38-45.

[15] AlbigesL, GoubarA, ScottV, et al.. Chk1 as a new therapeutic target in triple-negative breast cancer. Breast, 2014, 23(3): 250-258.

[16] HillSJ, DeckerB, RobertsEA, et al.. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov, 2018, 8(11): 1404-1421.

[17] Corrales-GuerreroS, CuiT, Castro-AceitunoV, et al.. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett, 2023, 570. 216308

[18] MosesN, ZhangM, WuJY, et al.. HDAC6 Regulates radiosensitivity of non-small cell lung cancer by promoting degradation of Chk1. Cells, 2020, 9102237.

[19] KooCY, MuirKW, LamEW. FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta, 2012, 1819(1): 28-37.

[20] VanGenderenC, HarknessTAA, ArnasonTG. The role of anaphase promoting complex activation, inhibition and substrates in cancer development and progression. Aging (Albany NY), 2020, 12(15): 15818-15855.

[21] ZhangYL, MaY, ZengYQ, et al.. A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics. Ann Transl Med, 2021, 9221704.

[22] BorhaniS, GartelAL. FOXM1: a potential therapeutic target in human solid cancers. Expert Opin Ther Targets, 2020, 24(3): 205-217.

[23] KalathilD, JohnS, NairAS. FOXM1 and cancer: faulty cellular signaling derails homeostasis. Front Oncol, 2020, 10. 626836

[24] GuL, LiuHM. Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy. World J Pediatr, 2020, 16(2): 113-119.

[25] LiuC, BargerCJ, KarpfAR. FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer. Cancers (Basel), 2021, 13123065.

[26] YangJ, LuoG, LiC, et al.. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma. BMC Cancer, 2022, 221589.

[27] ZengW, WangJ, YangJ, et al.. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Front Immunol, 2023, 141217590.

[28] TongX, WangS, LeiZ, et al.. MYOCD and SMAD3/SMAD4 form a positive feedback loop and drive TGF-beta-induced epithelial–mesenchymal transition in non-small cell lung cancer. Oncogene, 2020, 39(14): 2890-2904.

[29] KhanP, SiddiquiJA, KshirsagarPG, et al.. MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer, 2023, 2211.

[30] ZhangY, HunterT. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer, 2014, 134(5): 1013-1023.

[31] SmithJ, ThoLM, XuN, et al.. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res, 2010, 108: 73-112.

[32] ThoLM, LibertiniS, RamplingR, et al.. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene, 2012, 31(11): 1366-1375.

[33] LeeJH, ChoyML, NgoL, et al.. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci U S A, 2011, 108(49): 19629-19634.

[34] Al-KaabiMM, AlshareedaAT, JerjeesDA, et al.. Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. Br J Cancer, 2015, 112(5): 901-911.

[35] Madoz-GurpideJ, CanameroM, SanchezL, et al.. A proteomics analysis of cell signaling alterations in colorectal cancer. Mol Cell Proteomics, 2007, 6(12): 2150-2164.

[36] VerlindenL, Vanden BemptI, EelenG, et al.. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor/progesterone receptor /HER-2 breast carcinomas. Cancer Res, 2007, 67(14): 6574-6581.

[37] SriuranpongV, MutiranguraA, GillespieJW, et al.. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin Cancer Res, 2004, 10(15): 4944-4958.

[38] ZuoW, ZhangW, XuF, et al.. Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. Cancer Cell Int, 2019, 19240.

[39] WaltonMI, EvePD, HayesA, et al.. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Emicro-MYC driven B-cell lymphoma. Oncotarget, 2016, 7(3): 2329-2342.

[40] WaltonMI, EvePD, HayesA, et al.. CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clin Cancer Res, 2012, 18(20): 5650-5661.

[41] GalboPMJr, ZangX, ZhengD. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res, 2021, 27(9): 2636-2647.

[42] LiaoGB, LiXZ, ZengS, et al.. Regulation of the master regulator FOXM1 in cancer. Cell Commun Signal, 2018, 16157.

[43] GartelAL. FOXM1 in cancer: interactions and vulnerabilities. Cancer Res, 2017, 77(12): 3135-3139.

[44] YangC, ChenH, TanG, et al.. FOXM1 promotes the epithelial to mesenchymal transition by stimulating the transcription of Slug in human breast cancer. Cancer Lett, 2013, 340(1): 104-112.

[45] LiuY, LiuY, YuanB, et al.. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription. Oncotarget, 2017, 8(10): 17027-17037.

Funding

The present study was funded by the Suqian Science and Technology Program Project(K202008)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology